Universal Biosensors began its journey in the early 2000s, focusing on the research, development, and manufacture of biosensor test strips used in our hand-held analyzers for the diagnostic point-of-care (POC) market. UBI first developed a blood glucose monitoring product for LifeScan, Inc. (a Johnson & Johnson company) which was launched in 2010 under the global brand of OneTouch® Verio®. This product has sold more than 10 billion tests globally, with hundreds of millions of these tests initially being produced by UBI’s in-house production facility. In 2018, UBI ended its association with OneTouch® Verio® and pivoted this patented technology into other innovations.

In 2011, UBI began developing the Xprecia Stride™ blood coagulation analyzer in collaboration with Siemens Healthineers. Launched in 2015, Xprecia Stride™ was sold in 36 countries and currently has an install base exceeding 3,500 analyzers, servicing thousands of hospitals around the world.

Our core technology consists of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system using opposing electrodes that rapidly and accurately detects specific analytes in samples as small as a droplet (8 μL). This innovative technology was developed in our high-end research and development laboratory. A recent technology breakthrough has enhanced our detection limits by 1 billion times. Our technology offers affordable portability, speed, ease of use and reliability, with comparable precision and accuracy.